Elanco提供了2025全年的財務指引，具體如下： - 預計全年收入爲44.45億美元至45.1億美元，低於市場預期的45.33億美元。 - 調整後每股收益預計爲0.80美元至0.86美元，低於市場預期的0.90美元。 公司預計，由於外匯匯率的不利影響，將對收入帶來約1.1億美元的逆風。剔除這些不利影響後，公司仍預計收入將加速增長至中個位數。 公司預計，由於全球創新產品組合的推出，運營費用將按年增加約6%。全年調整後的息稅折舊及攤銷前收益（EBITDA）預計將包括約4500萬美元的不利外匯影響。 "我們專注於加速2025年有機的固定匯率收入增長，並繼續努力提高我們的盈利潛力和槓桿狀況，"Elanco動物健康的執行副總裁兼首席財務官Todd Young表示，"在應對動態的宏觀經濟環境時，我們對2025年展望的底層驅動因素仍充滿信心。唯一的調整是根據本月早些時候的匯率計算的增量貨幣逆風。我們預計2025年調整後的EBITDA將較歷史節奏更加偏向下半年，因爲強勢美元和我們在全球創新產品推出的戰略投資會推動創新收入貢獻的增加。"

以上內容來自Benzinga Earnings專欄，原文如下：

Elanco is providing financial guidance for the full year 2025, summarized in the following table, subject to the assumptions described below:

The company anticipates a headwind to revenue of approximately $110 million from the unfavorable impact of foreign exchange rates compared to prior year and since the November earnings call. Excluding the unfavorable impact of foreign exchange rates and the aqua divestiture, the company continues to expect revenue growth to accelerate to mid-single digits.

The company expects operating expenses to increase approximately 6% year over year in constant currency with strategic investment in the global launches of the innovation portfolio. Full year adjusted EBITDA includes an anticipated foreign exchange rate impact of approximately $45 million compared to prior year and since the November earnings call.

"We are focused on accelerating organic constant currency revenue growth for 2025, with continued efforts to improve our earnings potential and leverage profile," said Todd Young, Executive Vice President and CFO of Elanco Animal Health. "As we navigate a dynamic macroeconomic backdrop, we remain confident in the underlying drivers of the 2025 outlook provided during the November earnings call. The only adjustment we have made is for incremental currency headwinds using rates from earlier this month. We expect 2025 adjusted EBITDA to be more back half weighted than our historical cadence, with the stronger dollar and as our strategic investments in global launches drive the expected ramp for innovation revenue contributions."